Figures computed from official regulatory filings — .
Analysttarget 2 USD (-93%) · consensus 4.75/5 · 4 buy · 0 hold · 0 sell
Ownershipinsiders 17.94% · institutions 39.62% · short 0.6% of float
In USD · as of Oct 5, 2026
Ask the machine
Search and compare insider transactions, companies and their statistics in plain language. Your question becomes a query over available data, not a conversation or investment advice.
Data for Yarrow Bioscience, Inc. only. No web search. Global per-insider statistics are excluded.
An executed search uses one credit, even with no results. Errors and unsupported questions use no credits.
VYNE Therapeutics Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies to treat chronic inflammatory and immune-mediated conditions. The company's lead program is repibresib gel (VYN201), a topically administered small molecule pan-bromodomain and extra-terminal (BET) inhibitor soft drug to address diseases involving multiple and diverse inflammatory cell signaling pathways with low systemic exposure. It also develops VYN202, a BD2-selective oral small molecule BET inhibitor in Phase 1b trial for the acute control and chronic management of immune-mediated inflammatory conditions. VYNE Therapeutics Inc. was formerly known as Menlo Therapeutics Inc. and changed its name to VYNE Therapeutics Inc. in September 2020. The company was founded in 2003 and is based in Stewartsville, New Jersey.
Market information source · Oct 5, 2026
Periods recorded in the consulted sources. These do not certify the legal dates of name changes.
SEC company identity · Oct 5, 2026
Open-market timeline · full history
19 buys6 sells— close pricebar = usd volume, √ scaleclick a period to filter the table
| Insider | Type | Value · USD | Signals | Details |
|---|---|---|---|---|
| RTW Fund Group GP, LLC | OtherD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| RTW Fund Group GP, LLC | Other | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Ashiya Monatrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Zeronda Tyler | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Harsch Mutya | Other | $20.2K | Unusual size | SEC |
| Zeronda Tyler | Other | $20.2K | Unusual size | SEC |
| Stuart Iain | Other | $13.8K | Unusual size | SEC |
| Domzalski David | Other | $71.3K | Unusual size | SEC |
| Domzalski David | Other | $7.9K | SEC |
| Harsch Mutya | Other | $2.3K | SEC |
| Zeronda Tyler | Other | $2.3K | SEC |
| Stuart Iain | Other | $1.5K | SEC |
| Domzalski David | Award | $9.5K | SEC |
| Zeronda Tyler | Other | $2.4K | SEC |
| Domzalski David | Other | $8.5K | SEC |
| Stuart Iain | Other | $1.7K | SEC |
| Harsch Mutya | Other | $2.4K | SEC |
| Zeronda Tyler | Other | $4.6K | SEC |
| Domzalski David | Other | $7.4K | SEC |
| Harsch Mutya | Other | $2.1K | SEC |
| Stuart Iain | Other | $1.4K | SEC |
| LEPORE PATRICK Gtrack record | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| BARBARI SHARON SURREY | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Little Elisabeth Sandoval | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |
| Basta Steven L | AwardD (derivative) | n/a (Non-cash transaction: the filing states a price of zero (award, gift, exercise)) | SEC |